^
    17d
    Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=24, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • fludarabine IV
    18d
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Baylor College of Medicine | N=24 --> 14
    Enrollment change
    |
    GPC3 (Glypican 3) • IL15 (Interleukin 15)
    |
    AGAR T cells
    1m
    INTERCEPT: Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Seattle Children's Hospital
    New P1 trial
    2ms
    H-47757 AGAR: Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | Trial completion date: Feb 2040 --> Aug 2040
    Enrollment closed • Trial completion date
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    2ms
    CT0180-CG1203: Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, Zhejiang University | Trial completion date: Jun 2024 --> Jun 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • GPC3 (Glypican 3)
    |
    cyclophosphamide • CT0180
    3ms
    IMPACT: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (clinicaltrials.gov)
    P1, N=21, Not yet recruiting, Seattle Children's Hospital
    New P1 trial
    4ms
    Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV
    4ms
    DUET-1: BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=7, Active, not recruiting, Sotio Biotech Inc. | Recruiting --> Active, not recruiting | N=110 --> 7
    Enrollment closed • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • BRCA (Breast cancer early onset) • GPC3 (Glypican 3)
    |
    EGFR mutation • ALK translocation • BRCA mutation
    |
    cyclophosphamide • BOXR1030
    4ms
    Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (clinicaltrials.gov)
    P1, N=21, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3-CAR and IL15 plus IL21
    5ms
    BAH2573-104: Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=80, Recruiting, Essen Biotech
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    5ms
    Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Baylor College of Medicine | Trial completion date: Dec 2039 --> Dec 2040 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    AGAR T cells
    5ms
    ATHENA: A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=94, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide